Payment overview · 2025
General Payments
$519.74
28 reported records · 8 companies
Healthcare provider profile · identity verified
Nupur Dashottar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JEFFERSON HILLS, PA · NPI 1104844000
Verified facts
What the public records show
CMS Open Payments records show Nupur Dashottar, M.D. received $519.74 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 46.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $240.07 | 46.2% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.12 | 21.4% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.80 | 12.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.07 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.03 | 5.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $18.70 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.24 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.71 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $519.74 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $129.11 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.85 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.85 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.31 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.22 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.65 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 274 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
274 | 59 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 666 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 471 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 455 | 117 |
| Furosemide | Furosemide | 430 | 89 |
| Simvastatin | Simvastatin | 376 | 90 |
| Gabapentin | Gabapentin | 361 | 113 |
| Lisinopril | Lisinopril | 334 | 91 |
| Losartan Potassium | Losartan Potassium | 300 | 87 |
| Omeprazole | Omeprazole | 282 | 70 |
| Eliquis | Apixaban | 274 | 59 |
| Alprazolam | Alprazolam | 234 | 67 |
| Metformin Hcl | Metformin Hcl | 222 | 69 |
| Trazodone Hcl | Trazodone Hcl | 222 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 48 |
| Potassium Chloride | Potassium Chloride | 185 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 56 |
| Donepezil Hcl | Donepezil Hcl | 175 | 32 |
| Famotidine | Famotidine | 162 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 39 |
| Mirtazapine | Mirtazapine | 157 | 28 |
| Sertraline Hcl | Sertraline Hcl | 157 | 48 |
| Ozempic | Semaglutide | 156 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 33 |
| Jardiance | Empagliflozin | 151 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 31 |
| Prednisone | Prednisone | 130 | 69 |
| Buspirone Hcl | Buspirone Hcl | 127 | 24 |
| Tramadol Hcl | Tramadol Hcl | 125 | 52 |
| Carvedilol | Carvedilol | 123 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 28 |
| Montelukast Sodium | Montelukast Sodium | 105 | 31 |
| Metformin Hcl Er | Metformin Hcl | 101 | 25 |
| Alendronate Sodium | Alendronate Sodium | 97 | 28 |
| Topiramate | Topiramate | 88 | 21 |
| Allopurinol | Allopurinol | 83 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 16 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Azithromycin | Azithromycin | 74 | 62 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 68 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 22 |
| Synthroid | Levothyroxine Sodium | 68 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 40 |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 21 |
| Aripiprazole | Aripiprazole | 64 | 13 |
| Meloxicam | Meloxicam | 62 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Memantine Hcl | Memantine Hcl | 55 | 14 |
| Atenolol | Atenolol | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 53 | 11 |
| Cefuroxime | Cefuroxime Axetil | 53 | 44 |
| Bumetanide | Bumetanide | 52 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 15 |
| Celecoxib | Celecoxib | 51 | 17 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 33 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 13 |
| Amoxicillin | Amoxicillin | 45 | 41 |
| Spironolactone | Spironolactone | 44 | 15 |
| Clonazepam | Clonazepam | 43 | 13 |
| Linzess | Linaclotide | 43 | 12 |
| Glimepiride | Glimepiride | 41 | 11 |
| Irbesartan | Irbesartan | 41 | 11 |
| Nystatin | Nystatin | 39 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 16 |
| Erythromycin | Erythromycin Base | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Metolazone | Metolazone | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 14 |
| Myrbetriq | Mirabegron | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Baclofen | Baclofen | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Finasteride | Finasteride | 25 | 12 |
| Diltiazem 12hr Er | Diltiazem Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 14 |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Buprenorphine | Buprenorphine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $519.74 · 28 records | Novo Nordisk Inc | ABILIFY MAINTENA, ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error